Ligands for NKG2D-activating receptor (NKG2DL) can be regulated by DNA methylation (39), reducing the level of expression of NKG2D on the surface of AML cells or is released as soluble activating ligands into the TME, promoting ligand degradation and loss of NK cell cytotoxicity capacity (3, 42). The gene discussed is KLRK1; the disease is acute myeloid leukemia.